CAMBRIDGE, Mass. — Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children...

ALISO VIEJO, Calif. — Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of...

Iowa City, Iowa – The genetic defect responsible for cystic fibrosis (CF) may also directly contribute to the development of pancreatic cancer, according to a new study conducted in cell models. Researchers found that pancreatic cancer cells carrying CF-causing mutations grew faster and were more mobile than cancer cells without...